Oramed Pharmaceuticals, Inc. news

• Oral insulin program continues to advance with topline efficacy data expected in H2 2022
• Significant value creation opportunities through oral COVID-19 vaccine program and partnerships
• Well positioned to capitalize on opportunities with strong cash balance of ~$174 million as of December 3, 2021

• Protease inhibitor is a key component of Oramed’s PODTM technology that protects therapeutic proteins in the digestive system
• Oramed has already been granted this patent in the United States and Japan

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the 

Initial pre-purchase of 10 million doses of oral vaccines with a potential deal for further orders worth hundreds of millions of dollars

Prospective patient population of approximately 660 million throughout the Association of Southeast Asian Nations

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that i

Oravax’s oral vaccine targets three surface proteins, making it potentially more effective against current and future variants

Oravax’s oral vaccine should offer critical advantages, including logistics, distribution and delivery in less vaccinated regions, including Africa

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmace

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Netanel Derovan to serve as Chief Legal Officer (General Counsel) and Company Secretary, effective January 9, 2022. Mr. Derovan will oversee Oramed’s legal and corporate strategy affairs and provide strategic gui